of the combined company.
Steven Lutz, executive vice president, commercial operations of Cornerstone
BioPharma, will be executive vice president, manufacturing and trade of the
combined company. George Esgro, vice president, sales and marketing of
Cornerstone BioPharma, will be vice president, sales of the combined
company. David Price, executive vice president, finance and chief financial
officer of Cornerstone BioPharma, will be executive vice president, finance
and chief financial officer of the combined company. Scott Townsend, senior
vice president of legal affairs and general counsel of Critical
Therapeutics, will be executive vice president of legal affairs and general
counsel of the combined company.
"We are pleased to complete our merger with Critical Therapeutics and
begin executing on our business plan," said Mr. Collard. "Both companies
come off strong third quarter results, and we believe the growth prospects
for the combined company are significant."
Lazard acted as exclusive financial advisor and Wilmer Cutler Pickering
Hale and Dorr LLP acted as legal counsel to Critical Therapeutics.
Jefferies & Company, Inc. acted as exclusive financial advisor and Smith,
Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. acted as legal
counsel to Cornerstone BioPharma.
About Cornerstone Therapeutics
Cornerstone Therapeutics (Nasdaq: CRTX), headquartered in Cary, N.C.,
is a specialty pharmaceutical company focused on acquiring, developing and
commercializing prescription products for the respiratory market. The
Company currently promotes multiple marketed products in the United States
to respiratory-focused physicians and key retail pharmacies with its
specialty sales force. Cornerstone Therapeutics also has a de
Page: 1 2 3 4 5 Related medicine news :1
|SOURCE Cornerstone BioPharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 252
. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team3
. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets4
. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference5
. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting6
. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG7
. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia8
. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association9
. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 200710
. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization11
. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development